Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

This lawsuit is for anyone who acquired securities in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) from March 17, 2021 through May 7, 2024.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by failing to inform investors that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial.

On April 15, 2024, Marinus disclosed that its Phase 3 RAISE trial for the treatment of refractory status epilepticus (RSE) had not met early stopping criteria and that the Company would be “evaluating potential cost-saving strategies.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on May 8, 2024, Marinus announced several cost cutting measures, including the halting on clinical trial enrollment in the RAISE and RAISE II trials, reduced Company workforce, and operational changes. Additionally, the Company disclosed that it had stopped that Phase 3 Raise II trial. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) from March 17, 2021 through May 7, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.